Recursion Pharmaceuticals is trading 7.7% up at $3.98 on September 29, 2026, with no clear company-specific announcement explaining the intraday gain. - Recent coverage of its AI drug-discovery platform and REC-4881 trial progress predates this session and does not establish a cause. - Major indices are nearly flat in the supplied market context, so broader market direction does not clearly explain the move. The catalyst remains uncertain.